JavaScript is Disabled
Your browser's JavaScript functionality is disabled. It has to be enabled to use this function of ConfTool.
Here you can find information on how to enable JavaScript
If you have any problems, please contact the organizers at info@codan-consulting.com.

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

Daily Overview

Session

Session 3: Session 3: Modulators as Anticonvulsants

Time:

Thursday, 17/Sept/2026:

1:40pm - 3:45pm

Location: Aula Magna

Presentations

1:40pm - 2:05pm

TOWARDS A NEW CLASS OF KCNQ CHANNEL MODIFIERS FOR POTENTIAL THERAPEUTIC APPLICATIONS

Liana Mkrtchyan¹, Harutyun Sahakyan³, Jodene Eldstrom², Tatev Karapetyan¹, Astghik Abrahamyan¹, Karen Nazaryan³, Matthias Kneussel⁴, David Fedida², Vitya Vardanyan¹

¹Molecular Neuroscience Group, Institute of Molecular Biology, NAS, Armenia; ²Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Canada; ³Laboratory of Computational Modeling of Biological Processes, Institute of Molecular Biology, Armenia; ⁴Institute for Molecular Neurogenetics, Center for Molecular Neurobiology Hamburg, Germany

Session 3-1-Vardanyan.docx

2:05pm - 2:30pm

DEVELOPING ANTIEPILEPTIC DRUG CANDIDATES WITH THE NOVEL KCNQ2 AGONIST EBIO1 AS A LEAD

Huaiyu Yang

East China Normal University, China, People's Republic of

Session 3-2-Yang.docx

2:30pm - 2:55pm

FROM KV7.2 ACTIVATION TO INHIBITION BY CHEMICAL REMODELING

Carmine Ostacolo^1,7, Tania Ciaglia¹, Giusy Carleo², Zhenni Yang^3,4, Francesca Di Matteo¹, Federica De Rosa², Zhao-Bing Gao⁵, Marco D’Alì⁶, Demin Ma^3,4, Nannan Su⁶, Giacomo Pepe¹, Pietro Campiglia¹, Alessia Bertamino^1,7, Francesco Miceli^2,7, Jiangtao Guo^3,4, Nunzio Iraci^6,7, Maurizio Taglialatela^2,7

¹University of Salerno, Italy; ²University of Naples "Federico II", Italy.; ³Nanhu Brain-computer Interface Institute, China; ⁴Zhejiang University, China; ⁵Chinese Academy of Sciences, China; ⁶University of Messina, Italy; ⁷Keyon Lab, Italy

Session 3-3-Ostacolo.docx

2:55pm - 3:20pm

AKTIVA7E: A PROOF-OF-CONCEPT PHASE 1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, AND PHARMACOKINETICS OF QRL-101, A NOVEL KV7.2/7.3 MODULATOR, IN KCNQ2/KCNQ3 RELATED EPILEPSY

Taylor Gray, Samantha Rubino, Tracy Kemp, Thomas Bowman, Manoj Malhorta

QurAlis, United States of America

Session 3-4-Malhorta.docx

3:20pm - 3:45pm

ENHANCED SEIZURE SUSCEPTIBILITY AND COGNITIVE DEFICITS IN MICE EXPRESSING A GAIN-OF-FUNCTION EPILEPSY VARIANT IN PIP2-BINDING RESIDUE OF KV7.2

Tanveer Singh¹, Nicolette Amundsen¹, Sahil Malpotra¹, Hongyu Zhao¹, Annie Baker¹, Catherine Christian-Hinman^1,3, Hee Jung Chung^1,2,3

¹Dept. of Molecular and Integrative Physiology, University of Illinois at Urbana Champaign, United States of America; ²Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, United States of America; ³Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, United States of America

Session 3-5-Chung.docx